Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 89 results for vte

  1. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available

  2. Abdominal aortic aneurysm: diagnosis and management (NG156)

    This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.

  3. HemaClear for bloodless surgical field during limb surgery (MIB187)

    NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .

  4. What is the clinical and cost effectiveness of preoperative optimisation clinics for older people?

    therapy People who take a vitamin K antagonist are at high risk of venous thromboembolism or stroke and therefore, it is usual practice...

  5. For people with iron-deficiency anaemia, how long before surgery should oral iron supplementation be started, and what is the clinical and cost effectiveness of daily oral iron compared with oral iron given on alternate days?

    therapy People who take a vitamin K antagonist are at high risk of venous thromboembolism or stroke and therefore, it is usual practice...

  6. What is the most clinical and cost-effective strategy, as identified by a consensus survey, for the perioperative management of anticoagulation treatment in people taking a vitamin K antagonist with a target international normalised ratio (INR) of more than 3 who need bridging therapy?

    therapy People who take a vitamin K antagonist are at high risk of venous thromboembolism or stroke and therefore, it is usual practice...

  7. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

  8. Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

    Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.

  9. DOAC Dipstick for detecting direct oral anticoagulants (MIB248)

    NICE has developed a medtech innovation briefing (MIB) on DOAC Dipstick for detecting direct oral anticoagulants .

  10. Venous thromboembolism (surgical) (CG46)

    This guidance has been updated and replaced by NICE guideline CG92.

  11. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

  12. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (IPG593)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.

  13. Antenatal care (QS22)

    This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.

  14. Venous thromboembolism in adults: diagnosis and management (QS29)

    This quality standard has been updated and replaced by NICE quality standard QS201.

  15. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

    Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.